Biotin and Blood Tests: Assays Assume 30 mcg. Intakes Reach 10 mg.

Less than the intakes the published sources describe. FDA guidance states that devices using biotin/avidin technology have been assessed for biotin interference at the normal recommended daily doses of biotin — 30 micrograms per day, which results in plasma or serum biotin levels of less than 1 ng/mL — and that several reports have described unanticipated biotin interference with the performance of some devices due to consumer use of dietary supplements that result in levels above 1 ng/mL. UC Davis Health's clinical laboratory has put a working figure on it, reporting that the interference threshold at which some assays show more than a 10% change in results has been reported at 20 ng/mL, and that in people taking up to 10 mg daily serum biotin could reach the region of 30 ng/mL around eight hours after a dose. Ten milligrams is over three hundred times the 30 microgram figure the assays were validated against.

Any immunoassay built on biotin-streptavidin capture, which is a large and unglamorous share of routine testing. FDA guidance names hormone tests and tests for markers of cardiac health like troponin. Thyroid tests are the ones patients most often notice, because the pattern biotin produces can mimic hyperthyroidism convincingly enough to prompt treatment. The direction of the error is not fixed: FDA states that biotin levels in samples from patients who consume more than the recommended daily intake can cause falsely high or falsely low results, depending on the test principle. That is why there is no single rule of thumb to apply to your own results.

Because the error runs the wrong way. A falsely high result on most tests prompts more investigation, which is inefficient but safe. Troponin is the marker used to decide whether chest pain is a heart attack, and biotin interference on the affected assays pushes it down. A falsely low troponin does not trigger a second look — it closes the question. That asymmetry is why the FDA has published a list, current as of 21 June 2022, naming thirteen troponin assays that have not addressed the risk of biotin interference, from manufacturers including Roche Diagnostics, Ortho-Clinical Diagnostics, Princeton BioMeditech, Nano-Ditech and International Point of Care.

One death has been reported, and it should be described precisely rather than dramatically. The FDA warning followed a case in which a patient taking high-dose biotin died after a potentially falsely low troponin result. UC Davis Health's laboratory review of the episode states plainly that biotin interference was not confirmed and that the troponin measurements following the event were made post-mortem. So this is a reported case that prompted regulatory action, not a proven causal chain. It is also a single case set against a very large number of people taking biotin, which is worth holding in mind alongside it.

That is not what the FDA asks for, and this page is not going to invent a stronger instruction than the agency issued. The problem is a measurement problem, and the fix is disclosure: tell your doctor, and tell the person drawing your blood, that you take biotin and at what dose. If a test result does not fit the clinical picture — a thyroid panel that says one thing while you feel another — biotin is a specific thing to raise rather than a vague worry. Whether to pause it before a planned blood draw is a question for the clinician ordering the test, because the washout depends on your dose and on which assay their lab runs.

It is a separate question from whether biotin works, and the honest answer to that one is that true biotin deficiency is rare and the evidence for supplementation in people who are not deficient is thin. We cover that in more detail elsewhere. What this page adds is that the case for taking a large dose has to clear a second bar now: not just does it help, but is it worth carrying an interference risk into every blood test you have while you take it. For a documented deficiency that trade is easy. For hair thickness on spec, it is a real trade rather than a free one.

Some do now, and the FDA's own view is that this is not enough on its own. Its guidance states that labeling alone may not be sufficient to mitigate the risk of incorrect results from biotin interference in all cases, and that additional mitigation strategies may be considered where the risk could significantly affect patient or public health. The agency has since asked device makers to evaluate biotin up to 3,500 ng/mL — three times the maximum expected clinical concentration — which tells you how far above the 30 microgram assumption real-world intakes have moved.

Long enough to matter for a same-day test and not much longer, but the specifics vary and this page will not invent a number the sources do not give. Biotin is water-soluble and cleared renally, and UC Davis's figures describe levels measured around eight hours after ingestion, which is the window where a morning gummy and an afternoon blood draw collide. What the published sources here do not establish is a general washout period that is safe to quote for every dose and every assay. Ask the ordering clinician; they can check what their laboratory's assay tolerates.